TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 DKK)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
401,354
|
277,512
|
187,881 |
Financial expenses |
31,087
|
37,216
|
14,692 |
Earnings before taxes |
63,487
|
14,911
|
4,846 |
EBITDA |
43,052
|
32,460
|
-5,424 |
Total assets |
1,474,736
|
1,158,104
|
1,121,670 |
Current assets |
555,075
|
312,404
|
398,128 |
Current liabilities |
90,332
|
90,142
|
75,999 |
Equity capital |
1,306,437
|
955,664
|
934,691 |
- share capital |
541
|
509
|
548 |
Employees (average) |
130
|
114
|
92 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
88.6%
|
82.5%
|
83.3% |
Turnover per employee |
3,087
|
2,434
|
2,042 |
Profit as a percentage of turnover |
15.8%
|
5.4%
|
2.6% |
Return on assets (ROA) |
6.4%
|
4.5%
|
1.7% |
Current ratio |
614.5%
|
346.6%
|
523.9% |
Return on equity (ROE) |
4.9%
|
1.6%
|
0.5% |
Change turnover |
122,413
|
104,850
|
57,098 |
Change turnover % |
44%
|
61%
|
44% |
Chg. No. of employees |
16
|
22
|
29 |
Chg. No. of employees % |
14%
|
24%
|
46% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.